Literature DB >> 11753648

L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma.

T Wang1, L Fan, Y Watanabe, P McNeill, G R Fanger, D H Persing, S G Reed.   

Abstract

Using a combination of cDNA subtraction and microarray analysis, we report here the identification and characterization of L552S, an over-expressed, alternatively spliced isoform of XAGE-1 in lung adenocarcinoma. Real-time RT-PCR analysis shows that L552S is expressed at levels greater than 10-fold in 12 of 25 lung adenocarcinoma tumors compared with the highest expression level found in all normal tissues tested. L552S is expressed in both early and late stages of lung adenocarcinoma, but it was not detected in large cell carcinoma, small cell carcinoma, or atypical lung neuroendocrine carcinoid. The full-length cDNA for L552S comprises 770 bp and encodes a polypeptide of 160 amino acids. C-terminal 94 amino acids of L552S are identical to a cancer testis antigen, XAGE-1, found in Ewing's sarcoma. Genomic sequence analysis has revealed that L552S and XAGE-1 are alternatively spliced isoforms, and expression of both L552S and XAGE-1 isoforms are present in lung adenocarcinoma. Immunohistochemistry analysis using affinity purified L552S polyclonal antibodies demonstrated specific nuclear staining in 10 of 12 lung adenocarcinoma samples. Furthermore, antibody responses to recombinant L552S protein were observed in seven of 17 lung pleural effusion fluids of lung cancer patients. These results strongly imply that L552S protein is immunogenic and suggest that it might have use as a vaccine target for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753648     DOI: 10.1038/sj.onc.1204939

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  Hepatocellular carcinoma patients highly and specifically expressing XAGE-1 exhibit prolonged survival.

Authors:  Lei Gong; Jirun Peng; Zhuqingqing Cui; Pengcheng Chen; Hui Han; Dafang Zhang; Xisheng Leng
Journal:  Oncol Lett       Date:  2010-09-22       Impact factor: 2.967

2.  The biology of cancer testis antigens: putative function, regulation and therapeutic potential.

Authors:  Elisabetta Fratta; Sandra Coral; Alessia Covre; Giulia Parisi; Francesca Colizzi; Riccardo Danielli; Hugues Jean Marie Nicolay; Luca Sigalotti; Michele Maio
Journal:  Mol Oncol       Date:  2011-02-18       Impact factor: 6.603

3.  Inactivation of LLC1 gene in nonsmall cell lung cancer.

Authors:  Kyeong-Man Hong; Sei-Hoon Yang; Sinchita Roy Chowdhuri; Audrey Player; Megan Hames; Junya Fukuoka; Daoud Meerzaman; Tatiana Dracheva; Zhifu Sun; Ping Yang; Jin Jen
Journal:  Int J Cancer       Date:  2007-06-01       Impact factor: 7.396

4.  Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors.

Authors:  Shuichiro Sato; Yuji Noguchi; Nobuya Ohara; Akiko Uenaka; Michihide Shimono; Kazuhiko Nakagawa; Fumihito Koizumi; Toshiaki Ishida; Tadashi Yoshino; Yasushi Shiratori; Eiichi Nakayama
Journal:  Cancer Immun       Date:  2007-03-05

Review 5.  Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer.

Authors:  Ping Yang; Yingnan Qiao; Mei Meng; Quansheng Zhou
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.